目的 分析西安交通大學(xué)第一附屬醫(yī)院新型抗腫瘤藥物的使用情況，探討醫(yī)改政策下醫(yī)院新型抗腫瘤藥物的發(fā)展趨勢，為新型抗腫瘤藥物合理使用和規(guī)范化管理提供參考。方法 對2019—2021年西安交通大學(xué)第一附屬醫(yī)院新型抗腫瘤藥物的藥品規(guī)格、年銷售數(shù)量、年銷售金額、限定日劑量（DDD）、用藥頻度（DDDs）、日均費用（DDC）以及排序比（B/A）等進(jìn)行統(tǒng)計分析。結(jié)果 2019—2021年西安交通大學(xué)第一附屬醫(yī)院新型抗腫瘤藥物增加至48個品種，總體銷售金額呈逐年增長的趨勢。吉非替尼（易瑞沙）與伊馬替尼作為臨床一線小分子靶向藥物，使用頻率較大、其DDC最低，B/A 3年均大于2，顯示出良好的同步性。奧希替尼（泰瑞沙）用量增長較快、價格較其他小分子靶向藥物高，因此銷售金額連續(xù)2年排名第1名，但因其價格較高，B/A值僅為0.3，同步性較差。大分子單克隆抗體藥物曲妥珠單抗（赫賽?。┻B續(xù)3年銷售金額排名第1名，DDC值從2019年330.5元降至2021年250.0元，連續(xù)3年B/A為1；貝伐珠單抗（安可達(dá)與達(dá)攸同）作為國產(chǎn)新型抗腫瘤藥物，比進(jìn)口貝伐珠單抗（安維?。┦褂昧扛?、DDDs大、DDC低。結(jié)論 西安交通大學(xué)第一附屬醫(yī)院新型抗腫瘤藥物可供臨床使用的品種快速增多。新醫(yī)改政策實施以來，新型抗腫瘤藥物價格下降明顯，國家談判藥物以及“4＋7”藥物年使用量逐漸增加，符合國家政策要求趨勢及當(dāng)前腫瘤治療的實際。

Objective To analyze the application situation of new antitumor drugs in the First Affiliated Hospital of Xi’an Jiaotong University, investigate the development tendency of new antitumor drugs in hospitals under the medical reform policy, and provide references for the rational use and standardized management of new antitumor drugs. Methods The new antitumor drugs used in the First Affiliated Hospital of Xi’an Jiaotong University from 2019 to 2021 were analyzed statistically in respect of drug specifications, annual sales volume, annual consumption sums, defined daily dose (DDD), medication frequency (DDDs), average daily cost (DDC) and the ranking ratio (B/A) of new antitumor drugs. Results The number of new anti-tumor drugs increased to 48 varieties from 2019 to 2021, and the consumption sums were increasing year by year in the First Affiliated Hospital of Xi’an Jiaotong University. Gefitinib (Iressa) and Imatinib were clinical first-line small-molecule targeted drugs with high frequency of use, the lowest DDC, and B/A greater than 2 in three years, shows good synchronization. Osimertinib (Taressa) has grown rapidly in dosage and its price is higher than other small molecule targeted drugs, so its sales amount has ranked first for two consecutive years, shows poor synchronizationhas. The trastuzumab was a macromolecular monoclonal antibody drug with the highest frequency of clinical use for three consecutive years. The DDC value has dropped from 330.5 yuan in 2019 to 250.0 yuan in 2021, and the B/A = 1 for three consecutive years. bevacizumab (Ankeda and Dayoutong), as new domestic anti-tumor drugs, have higher usage , larger DDDs, lower DDC than imported bevacizumab (Avastin). Conclusion The varieties of new anti-tumor drugs available for clinical use in the First Affiliated Hospital of Xi'an Jiaotong University are increasing rapidly. Since the implementation of the new medical reform policy, the price of new anti-tumor drugs has been dropped significantly, and the annual usage of nationally negotiated drugs and “4 + 7” drugs has been gradually increasing, which is in accord with the tendency of national policy requirements and the reality of current tumor treatment.

R979.1

陜西省重點研發(fā)計劃項目(2020SF-210)